Skip to main content

Indian Pharma Network

18008891064
info@indianpharmanetwork.in
For Careers: +91-9220822566

Facebook Twitter Linkedin Whatsapp

Menu

Home
About Us
Product List
Blog
Support & FAQs
News
Contact Us

Search

Close

Tag

Wyost (denosumab-bbdz)

Jubbonti (denosumab-bbdz) and Wyost (denosumab-bbdz)

News

FDA Approves First Interchangeable Biosimilars for Osteoporosis and Cancer Patients

Related Posts

Atriance Market Set for...

The pharmaceutical landscape is witnessing...

Padcev (Enfortumab vedotin) in...

Enfortumab vedotin is supplied under...

X-linked hypophosphatemia (XLH) symptoms, diagnosis and treatment – Indian Pharma Network

X-Linked Hypophosphatemia: Symptoms, Diagnosis,...

X-linked Hypophosphatemia (XLH) is a...

Advancing Cancer Care: Nelarabine...

Nelarabine Injection, a ground-breaking oncology...

Tukysa Improves Survival for...

Key Takeaways: The new cancer...

Recent Posts

FDA Approves Emcitate (Tiratricol): First Treatment for MCT8 Deficiency (Allan-Herndon-Dudley Syndrome)
FDA Approves Isembyld (Apitegromab-mstn), First Muscle-Targeted Therapy for Spinal Muscular Atrophy
FDA Approves First Drug to Treat Alexander Disease: Zanvastro (Zilganersen)
कैंसर से पहले शरीर देता है ये 5 संकेत, न करें नज़रअंदाज़
Trodelvy in India: A Sourcing Guide for Hospitals Treating Triple-Negative Breast Cancer

Indian Pharma Network helps in accessing new products in India. These products are launched and approved recently in USA or Europe but yet to be approved in India. We help in accessing these new launches through named patient import

IMPORTED MEDICINES

Trodelvy in India
Braftovi in India
Trientine in India
Blincyto in India
vyloy in India
Orencia in India
Welireg in India

Kineret in India
Lumakras in India
Elahere in india
Imdeltra In India
Truqap in India
Lytgobi in India
Increlex in India

BEST TREATMENT

Muscular Dystrophy
Bladder Cancer
Brain Tumor
Cervical Cancer
Prostate Cancer
Breast Cancer
Colorectal Cancer
Wilson’s Disease

Rheumatoid Arthritis
Lung Cancer
Ovarian Cancer
Acute Myeloid Leukemia
Thyroid cancer
Kidney cancer
Duchenne Muscular Dystrophy

TOP ARTICLES

Eculizumab
HMPV
aHUS
PNH
Melanoma
PAH
Trodelvy

PBC
MPOX Virus
Counterfeit Drugs
Nelarabine
Polivy

FDA Drug Approvals

Lumakras
Gavreto
symbravo
Grafapex
Romvimza
Alhemo
Zepzelca
Agilus

Datroway
Brynovin
Gomekli
Alyftrek
Tryngolza
Columvi
Rinvoq
Lazcluze

Latest News

Trusted Global Supplier from India
How to Get a Pharmaceutical Import License in India?
Takeda’s Qdenga Vaccine
Manufacture Risdiplam for (SMA)
Wilson’s Disease: Neurological Symptoms, Early Signs, and Treatment Options
Pharmaceutical Fraud: A Global Perspective

Indian Pharma Network

Indian Pharma Network Tower A 905, I-Thum Business Park, Block A, Sector 62, Noida, Uttar Pradesh 201301

Mission Vision and value

Mobile/WhatsApp/Phone

M: +91 9654860915
M: +91 9310090915

Privacy Policy

Free Customer Support

info@indianpharmanetwork.in

Terms and Conditions

Disclaimer : Website: indianpharmanetwork.in is a pharmaceutical trading entity that procures and supplies prescribed medicines strictly from manufacturers or duly authorized distributors. The company does not manufacture, formulate, or alter any pharmaceutical products. All trademarks, brand names, and product names referenced remain the property of their respective owners. Any use of such names is solely for identification purposes and is in compliance with the provisions of the Trademark Act, 1999, including principles of fair use. Website: indianpharmanetwork.in does not claim ownership of, nor does it assert any rights over, any patents associated with the products supplied. Compliance with patent laws, including the Patents Act, 1970, rests with the respective patent holders, manufacturers, or marketing authorization holders. The company facilitates access to certain medicines, including new launches, through legally permissible channels such as named patient import, strictly against valid prescriptions and in accordance with applicable laws and regulatory requirements. Nothing herein shall be construed as an inducement or authorization to infringe any intellectual property rights.

© 2026 Indian Pharma Network.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.